ReviewMediterranean journal of rheumatology2022
Axial Disease in Psoriatic Arthritis: how can we Define it, and does it have an Impact on Treatment?
Review in Mediterranean journal of rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Development of structural damage in the spine in patients with PsA: findings from a longitudinal cohort study.Rheumatology (Oxford, England) · 2026Article
- Beyond Clinical Trials: Experience with Bimekizumab in 3 Challenging Cases of Psoriatic Arthritis.Mediterranean journal of rheumatology · 2026Article
- Pivotal role of the synovioentheseal complex in the imaging of arthritis and rheumatic diseasesDiagnostic and interventional radiology (Ankara, Turkey) · 2024Review
- Axial Disease in Psoriatic Arthritis: A Challenging Domain in Clinical Practice.Diagnostics (Basel, Switzerland) · 2024Review
- Unmet needs in psoriatic arthritis, a narrative review.Archives of rheumatology · 2024Article
- JAK Inhibitors for the Treatment of Axial Spondyloarthritis.Mediterranean journal of rheumatology · 2023Review
- Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease.Rheumatology international · 2023Article
- MRI Findings in Axial Psoriatic Spondylarthritis.Diagnostics (Basel, Switzerland) · 2023Review
- Management of psoriatic arthritis: a consensus opinion by expert rheumatologists.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Spondyloarthritis (SpA) represents a group of rheumatic inflammatory entities that share clinical, laboratory and imaging features, including Psoriatic Arthritis (PsA). Axial involvement may occur in up to 50% of patients with PsA (axPsA), causing inflammatory back pain, stiffness and changes on imaging. Whether axial SpA (axSpA) with psoriasis represents a distinct entity than axPsA is a matter of debate, since similarities and differences have been reported in terms of clinical expression and imaging. Patients with radiographically axPsA show lower prevalence of inflammatory b ack pain, lumbar and buttock pain in comparison with axSpA. In addition, imaging features differ between axPsA and axSpA, with less sacroiliitis in axPsA and more asymmetrical, chunky syndesmophytes which are predominant at the cervical spine location. Data on treatment efficacy and management recommendations are extrapolated from studies on axSpA, and only one published randomized clinical trial is dedicated specifically to axPsA to date.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.